Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Brookfield Private Equity Fund Capital Raise of $6.2M
Brookfield Private Equity Fund LP sold unregistered limited partnership units for aggregate consideration of approximately $6.2 million on October 1, 2026. The sale was part of a continuous private offering that has raised approximately $420.6 million for the broader BPE Program since November 2025.
Hashdex Nasdaq CME Crypto Index ETF entered into an Authorized Participant Agreement with Jane Street Capital, LLC. The agreement establishes the procedures for Jane Street to create and redeem baskets of the ETF's common shares, facilitating the fund's ongoing capital issuance and liquidity.
Pelthos Therapeutics M&A Deal with Castle Creek Biosciences, Inc.
Pelthos Therapeutics has entered into a definitive agreement to acquire Castle Creek Biosciences in a merger transaction. Castle Creek stockholders will receive 5.2 million shares of Pelthos common stock plus potential milestone payments totaling up to $300 million tied to the clinical and commercial success of the D-Fi gene therapy franchise. The deal combines Pelthos' commercial dermatology infrastructure with Castle Creek's late-stage cell and gene therapy platform for rare skin diseases.
OpenWorld, Inc. entered into a securities purchase agreement for a $3.5 million registered direct offering with a single institutional investor. The company is selling 2,517,985 shares of common stock at a combined price of $1.39 per share, including accompanying Series A and Series B warrants. Proceeds are intended for real-world asset growth initiatives and general corporate purposes.
TerraVolt Holdings entered into option agreements to acquire 1,077 acres in Cassia County, Idaho, for the development of a 240 MW gas-powered digital infrastructure campus. The company paid a $150,000 option fee for the site, which is designed to operate behind-the-meter to avoid grid interconnection delays. The total purchase price for the land is approximately $32.31 million ($30,000 per acre), payable in a mix of cash and a convertible secured promissory note.
Pluri Inc. entered into a partnership agreement with ZEO ScientifiX to grant ZEO an exclusive license to manufacture and commercialize Pluri's regenerative medicine portfolio in the United States. In exchange, Pluri will receive a 50% equity stake in ZEO and the right to designate four out of seven board members, while ZEO will receive approximately 9% of Pluri's outstanding common shares.
Zeo ScientifiX entered into a definitive strategic agreement with Pluri Inc. to expand U.S. manufacturing and commercialization of regenerative medicine products. As part of the license-for-equity transaction, Pluri will grant ZEO an exclusive license to its proprietary 3D cell expansion platform in exchange for a 41% equity stake in ZEO and a share swap involving 4% of each company's outstanding stock.
Organon & M&A Deal with Sun Pharmaceutical Industries Limited
Organon & Co. provided a status update on its pending merger with Sun Pharmaceutical Industries Limited, noting that it has suspended customary earnings calls and press releases due to the transaction. The company furnished supplemental non-GAAP financial metrics for the third quarter of 2026 in lieu of a formal earnings release while the merger remains active.
Azenta acquired SynPlexity Inc., a synthetic biology company specializing in high-throughput gene libraries, and entered into an exclusive licensing and supply agreement with Elegen Corp. for its cell-free DNA manufacturing technology. The combined strategic investments involve an expected capital deployment ranging from $32 million to $71 million to expand Azenta's GENEWIZ gene synthesis capabilities and regional production capacity.
Game Your Game Inc. received a deficiency notice from Nasdaq on October 27, 2026, because its common stock failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days. The company has 180 calendar days, until April 26, 2027, to regain compliance by maintaining a $1.00 closing bid price for at least 10 consecutive business days. Separately, the company appointed Veronica V. Montenegro as an independent director and chairperson of the nominating and corporate governance committee.
Lci Industries M&A Deal with Patrick Industries, Inc.
LCI Industries announced that its Board of Directors unanimously rejected an unsolicited $101 per share cash acquisition proposal from Monomoy Capital Partners, determining it was not a superior proposal. The company reaffirmed its commitment to its existing merger agreement with Patrick Industries, which is expected to close in the first half of 2027 and generate $150 million in annual cost synergies.
Churchill Capital Corp XI Signs $465M M&A Deal with Agility Robotics, Inc.
Churchill Capital Corp XI provided a status update on its pending merger with Agility Robotics, announcing an expected gross capital raise of $465 million following the expiration of the redemption deadline. The business combination is expected to close on November 4, 2026, with the combined company trading on Nasdaq under the ticker 'AGLT' starting November 5, 2026.
Acumen Pharmaceuticals announced that its Phase 2 ALTITUDE-AD clinical trial of sabirnetug for early Alzheimer’s disease failed to meet its primary endpoint of cognitive and functional decline improvement. The trial also failed key secondary endpoints, leading the company to cease development of sabirnetug and implement cash conservation measures while exploring strategic options.
LyondellBasell Industries Divestiture to Valero Energy Corporation for $320M
LyondellBasell entered into an agreement to sell its subsidiary Houston Refining, L.P., which includes the former Houston refinery site, to a subsidiary of Valero Energy Corporation for $320.5 million. The transaction follows the company's shutdown of refining operations at the site in February 2025 and is expected to close in the fourth quarter of 2026.
Value
$320M
Counterparty
Valero Energy Corporation
“In an evolving macroeconomic environment, we delivered another quarter of strong earnings and robust cash conversion through disciplined execution underscored by the strength of our global, cost-advantaged portfolio.”
Peter Vanacker, LYB chief executive officer
“We are leveraging the flexibility and resilience of our leaner structure by optimizing feedstocks, directing products to the most attractive markets and aligning operating rates with demand.”
Valero Energy Signs $320M M&A Deal with LyondellBasell Industries N.V.
Valero Energy Corporation has entered into a definitive agreement to acquire the 700-acre Houston refinery facility from LyondellBasell for $320.5 million. Valero plans to restart 165,000 barrels per day of light sweet crude processing capacity at the site by year-end 2027, with future opportunities to invest in heavy sour crude processing. The deal is expected to close by the end of 2026, subject to regulatory approvals.
Artificial Intelligence Technology Solutions (AITX) announced that its subsidiary, Robotic Assistance Devices (RAD), will unveil RAIA, a portable solar-powered security tower, on November 9, 2026. The system is designed to ship in two boxes and deploy without a trailer, targeting the $1.49 billion mobile surveillance tower market with rental costs estimated to be up to 70% lower than competitors.
Armlogi Holding Corp. received a notification from Nasdaq confirming it has regained compliance with the $1.00 minimum bid price requirement for continued listing. The company's common stock maintained a closing bid price of at least $1.00 for 10 consecutive business days from October 15 to October 28, 2026.
Revolve Group disclosed a cybersecurity incident involving unauthorized access to its systems where an actor obtained customer names, contact information, and payment card details. The company has remediated the activity, notified law enforcement, and engaged external experts to investigate. Revolve stated the incident has not caused operational disruptions and is not expected to have a material impact on its business.
Ingram Micro delivered record Q3 results with 21% revenue growth, driven by a 160% surge in AI infrastructure and GPU sales, leading to raised full-year guidance.
T3 Defense Inc. raised $10 million in gross proceeds through a private placement of 200 units to an accredited investor. Each unit consists of one share of Series B Convertible Preferred Stock and warrants to purchase 14,851 shares of common stock. The company received net proceeds of approximately $6.6 million after deducting placement agent fees and the repayment of an existing term note.
Zoomcar Holdings completed the seventh closing of its private placement of Series A units, raising $75,000 in gross proceeds. Each unit consists of one share of Series A Convertible Preferred Stock and a warrant to purchase 20,000 shares of common stock. The offering has a total capacity of up to $5 million, plus a $5 million overallotment option, and has been extended to November 16, 2026.
Aldel Financial II Inc. received a delisting notice from Nasdaq on October 28, 2026, with trading of its securities expected to be suspended on November 6, 2026, due to failure to meet listing requirements. Separately, the company issued a $1.0 million unsecured promissory note to its sponsor, Aldel Investors II LLC, to fund working capital and trust account extension payments.
ProKidney Corp. entered into an Open Market Sale Agreement with Jefferies LLC to establish an at-the-market (ATM) offering program. Under the agreement, the company may offer and sell shares of its Class A common stock with a maximum aggregate offering price of up to $200 million. Jefferies will act as the sales agent and receive a commission of up to 3.0% of the gross proceeds from any shares sold.
Meta Platforms, Inc. completed a public offering of 250,000,000 depositary shares, each representing a 1/20th interest in its 6.50% Series A Mandatory Convertible Preferred Stock. The offering raised $12.5 billion in gross proceeds (based on the $1,000 liquidation preference per full preferred share) to be used for general corporate purposes. The underwriters were granted a 30-day option to purchase an additional 37.5 million depositary shares to cover over-allotments.
Verisk Analytics issued a status update regarding its pending acquisition of AccuLynx following a Delaware Supreme Court order that affirmed a previous Chancery Court judgment. The company stated it will proceed in accordance with the court's order, though the transaction remains subject to FTC review and customary closing conditions.
Propanc Biopharma received a delisting notice from Nasdaq on October 23, 2026, for failing to maintain the $1.00 minimum bid price requirement. Because the company already completed a reverse stock split within the past year, it is ineligible for the standard 180-day grace period and faces delisting on November 2, 2026. The company intends to appeal the determination to a hearings panel, which will stay the delisting process.
Glucotrack received notice from a Nasdaq Hearings Panel that its securities will be delisted after failing to maintain a $1.00 minimum bid price through the required exception period. Trading on Nasdaq will be suspended on October 30, 2026, and the company plans to transition its common stock to the OTC Markets Group (OTCID).
BranchOut Food Inc. completed its public offering following the full exercise of the underwriters' over-allotment option for 441,176 additional shares. The exercise generated $0.75 million in additional proceeds, bringing the total gross proceeds of the offering to approximately $5.75 million. The shares were sold at a public offering price of $1.70 per share.
Iovance Biotherapeutics announced updated Phase 2 IOV-LUN-202 trial results for lifileucel in non-squamous metastatic non-small-cell lung cancer, showing a 24.6% objective response rate in the broader population. A retrospective analysis identified a biomarker-enriched subgroup (KRAS/HER2 wild-type smokers) with a significantly higher 59.1% response rate. The company plans to launch a prospective registrational cohort called POSITILITY in November 2026 and submit a supplemental BLA in 2027.